Tags:AdTechDevelopmentInformationLabMedTechProductResearch
Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Our lead product is ILUVIEN, now approved for marketing in the U.S. and 15 European countries for the treatment of diabetic macular edema.
Likes
3261
Location: United States, Georgia, Alpharetta
Member count: 201-500
Phone: +1 678-990-5740
Founded date: 2003

Investors 4

Mentions in press and media 10

DateTitleDescriptionCategoryAuthorSource
02.06.2022Alimera Sc...ATLANTA, June 02, 2022 (GLOBE ...--globenewsw...
14.04.2021ALIMERA SC...Alimera grants exclusive licen...--marketscre...
14.04.2021Alimera Sc...Alimera Sciences, Inc. (Nasdaq...--marketscre...
18.02.2014Alimera ra...Alimera Sciences (NSDQ:ALIM) r...-Arezu Sarv...massdevice...
03.10.2012Biotech co...Solution/Product: The company ...--medcitynew...
23.04.2010Morning Re...Why people hate insurance comp...--medcitynew...
18.03.2008Life-scien...TODAY’S HEADLINES: Luminous Me...--venturebea...
17.01.2008Life scien...TODAY’S HEADLINES: TransEnter...--venturebea...
-Biotech co...Alimera Sciences, a public com...--medcitynew...
-Morning Re...Highlights of the important an...--medcitynew...